Thomas C. Fisher
Geen lopende functies
Profiel
Thomas C.
Fisher worked as a Senior Vice President-Operations at Martek Biosciences Corp.
and as a Vice President-Technical Operations at DuPont Merck Pharmaceutical Co. He completed his undergraduate degree at Waynesburg College and his graduate degree at West Virginia University.
Eerdere bekende functies van Thomas C. Fisher
| Bedrijven | Functie | Einde |
|---|---|---|
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
Martek Biosciences Corp.
 Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Operationeel Directeur | - |
Opleiding van Thomas C. Fisher
| West Virginia University | Graduate Degree |
| Waynesburg College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
